Bio-Path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. The Company’s initial focus is on cancer. Bio-Path’s lead product candidate, BP1001 (Liposomal Grb-2), is completing the safety segment of the Phase II for AML in combination with the frontline therapy for induction therapy ineligible patients. A second Phase II safety segment for CML will start in the first half of 2016. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.
Bio-Path's antisense DNA - liposomal delivery technology is called DNAbilize™ and is available for licensing for drug development. DNAbilize™ offers distinct advantages over the current antisense and RNAi therapeutics in development. DNAbilize™ chemistry has shown no toxicity in patients to date. This allows for higher dosing to a therapeutic level compared to the more toxic approaches including phosphorothioate DNA. DNAbilize™ also has the advantage of systemic distribution and allows for targeting genes involved in diseases beyond the liver. Systemic level diseases and disorders can be targeted using DNAbilize™. We are interested in collaborations to develop therapeutics using DNAbilize.
Company Growth (employees)